Literature DB >> 20019858

Use of palivizumab in children with congenital heart disease.

.   

Abstract

Entities:  

Year:  2003        PMID： 20019858      PMCID： PMC2795277          DOI： 10.1093/pch/8.10.631

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN： 1205-7088            Impact factor:   2.253


× No keyword cloud information.
  20 in total

1.  Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent?

Authors:  B Law; N Macdonald; J Langley; I Mitchell; D Stephens; E Wang; J Robinson; F Boucher; J McDonald; S Dobson
Journal:  Paediatr Child Health       Date:  1998-11       Impact factor: 2.253

2.  Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants.

Authors: 
Journal:  Paediatr Child Health       Date:  1999-10       Impact factor: 2.253

3.  Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening.

Authors:  C A Altman; J A Englund; G Demmler; K L Drescher; M A Alexander; C Watrin; T F Feltes
Journal:  Pediatr Cardiol       Date:  2000 Sep-Oct       Impact factor: 1.655

4.  Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database.

Authors:  B J Law; E E Wang; N MacDonald; J McDonald; S Dobson; F Boucher; J Langley; J Robinson; I Mitchell; D Stephens
Journal:  Pediatrics       Date:  1997-03       Impact factor: 7.124

Review 5.  Respiratory syncytial virus infection.

Authors:  E A Simoes
Journal:  Lancet       Date:  1999-09-04       Impact factor: 79.321

6.  Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection.

Authors:  E E Wang; B J Law; F D Boucher; D Stephens; J L Robinson; S Dobson; J M Langley; J McDonald; N E MacDonald; I Mitchell
Journal:  J Pediatr       Date:  1996-09       Impact factor: 4.406

7.  Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection.

Authors:  Thierry Lacaze-Masmonteil; Juergen Seidenberg; Ian Mitchell; Veerle Cossey; Martin Cihar; Michal Csader; Rienk Baarsma; Marques Valido; Paul F Pollack; Jessie R Groothuis
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

8.  Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group.

Authors:  E A Simoes; H M Sondheimer; F H Top; H C Meissner; R C Welliver; A A Kramer; J R Groothuis
Journal:  J Pediatr       Date:  1998-10       Impact factor: 4.406

9.  Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.

Authors:  J R Groothuis; E A Simoes; M J Levin; C B Hall; C E Long; W J Rodriguez; J Arrobio; H C Meissner; D R Fulton; R C Welliver
Journal:  N Engl J Med       Date:  1993-11-18       Impact factor: 91.245

10.  Risk of primary infection and reinfection with respiratory syncytial virus.

Authors:  W P Glezen; L H Taber; A L Frank; J A Kasel
Journal:  Am J Dis Child       Date:  1986-06
View more
  9 in total

1.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

2.  Preventing hospitalizations for respiratory syncytial virus infection.

Authors:  Joan L Robinson; Nicole Le Saux
Journal:  Paediatr Child Health       Date:  2015 Aug-Sep       Impact factor: 2.253

3.  Prevention of respiratory syncytial virus infection.

Authors:  L Samson
Journal:  Paediatr Child Health       Date:  2009-10       Impact factor: 2.253

4.  Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.

Authors:  Andrew Warren; Joanne M Langley; Wanda Thomas; Jeff Scott
Journal:  Can J Cardiol       Date:  2007-05-01       Impact factor: 5.223

5.  Palivizumab use among children with congenital heart disease in Quebec: Impact of Canadian guidelines on clinical practice.

Authors:  Marc Bellavance; Charles V Rohlicek; Jean-Luc Bigras; Jean-Marc Côté; Marc Paquet; Marc H Lebel; Andrew S Mackie
Journal:  Paediatr Child Health       Date:  2006-01       Impact factor: 2.253

6.  Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations.

Authors:  B Paes; I Mitchell; A Li; K L Lanctôt
Journal:  Eur J Pediatr       Date:  2011-12-28       Impact factor: 3.183

7.  Incidence and risk factors of hospitalization for bronchiolitis in preterm children: a retrospective longitudinal study in Italy.

Authors:  Patrizio Pezzotti; Jessica Mantovani; Nicoletta Benincori; Eleonora Mucchino; Domenico Di Lallo
Journal:  BMC Pediatr       Date:  2009-09-10       Impact factor: 2.125

Review 8.  Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV).

Authors:  Lina Bollani; Eugenio Baraldi; Gaetano Chirico; Andrea Dotta; Marcello Lanari; Antonello Del Vecchio; Paolo Manzoni; Antonio Boldrini; Piermichele Paolillo; Sandra Di Fabio; Luigi Orfeo; Mauro Stronati; Costantino Romagnoli
Journal:  Ital J Pediatr       Date:  2015-12-15       Impact factor: 2.638

9.  Palivizumab's real-world effectiveness: a population-based study in Ontario, Canada, 1993-2017.

Authors:  Tiffany Fitzpatrick; James Dayre McNally; Therese A Stukel; Jeffrey C Kwong; Andrew S Wilton; David Fisman; Astrid Guttmann
Journal:  Arch Dis Child       Date:  2020-08-28       Impact factor: 3.791
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.